title: [Switch of methoxy-polyethylene-glycol-epoetin beta to darbepoetin alfa in 263 dialysis patients].
abstract: In early 2012, due to national supply disruption, the methoxy-polyethylene glycol-epoetin beta (CERA) was no longer available and has been replaced by darbepoetin alfa (DA) in all dialysis patients. Official recommendations for the replacement of one by the other is missing or unclear. On this occasion, we wanted to examine how the shift from CERA to DA was done in terms of dose conversion factor and the other factors that could have influenced the dose of DA prescribed (hemoglobin, patient weight, dose of CERA). This retrospective multicenter open conducted in six dialysis centers in Alsace is the first large study (n=263) that evaluated the switch from CERA to DA in all chronic hemodialysis patients. We found that the instantaneous ratio of dose adjustment is close to 1 and that nephrologists are mainly based on the dose of CERA for determining the DA dose, before hemoglobin and weight. However, establishing a true dose-response ratio between the two molecules requires a long term prospective study.
authors.affiliation: Service de pharmacie-stérilisation, centre hospitalier de Haguenau, 64, avenue du Professeur-Leriche, 67500 Haguenau, France.
authors.forename: J
authors.initials: J
authors.lastname: Rieger
authors.affiliation: Service de néphrologie, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, BP 426, 67091 Strasbourg cedex, France.
authors.forename: T
authors.initials: T
authors.lastname: Krummel
authors.affiliation: Service de néphrologie, clinique St-Anne, rue Philippe-Thyss, 67000 Strasbourg, France.
authors.forename: P
authors.initials: P
authors.lastname: Petitjean
authors.affiliation: Service de néphrologie, hôpital Edouard-Muller, 20, avenue du Dr-Laennec, 68070 Mulhouse, France.
authors.forename: F
authors.initials: F
authors.lastname: Chantrel
authors.affiliation: Service de néphrologie, centre hospitalier de Haguenau, 64, avenue du Professeur-Leriche, 67500 Haguenau, France. Electronic address: yves.dimitrov@ch-haguenau.fr.
authors.forename: Y
authors.initials: Y
authors.lastname: Dimitrov
mesh_terms: D000368:Aged; D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D000068256:Darbepoetin alfa / Q000627:therapeutic use*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects; D012189:Retrospective Studies
chemical_list: D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D000068256:Darbepoetin alfa
keywords: Agent stimulant l’érythropoïèse; Anemia; Anémie; Chronic dialysis; Erythropoiesis stimulating agents; Erythtropoietin; Hemoglobin; Hémodialyse chronique; Hémoglobine; Érythropoïétine